12/03/21 7:30 AMNasdaq : ZLAB Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian CancerZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by China’sRHEA-AIneutral
11/30/21 7:30 AMNasdaq : ZLAB clinical trialZai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer• PRIME study demonstrates that niraparib treatment had a clinically meaningful and statistically significant benefit in improving progression-free survival in the overall study population regardless of biomarker status when compared to placebo • Treatment was tolerable in the populationRHEA-AIneutral
11/23/21 7:30 AMNasdaq : ZLAB conferencesZai Lab Announces Upcoming Presentations at December Investor ConferencesZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtualRHEA-AIneutral
11/22/21 7:30 AMNasdaq : ZLAB managementZai Lab Appoints Richard Gaynor, MD, to its Board of DirectorsZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it has appointed Richard Gaynor, M.D., to its Board of Directors.RHEA-AIvery positive
11/16/21 7:30 AMNasdaq : ZLAB clinical trialZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDPZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been dosed in the Greater China portion ofRHEA-AIneutral
11/15/21 7:30 AMNasdaq : ZLAB clinical trialZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in PemphigusZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been treated in the Greater China portion ofRHEA-AIneutral
11/11/21 7:30 AMNasdaq : ZLAB clinical trialZai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune ThrombocytopeniaZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. The company announced today that the first patient with primary immuneRHEA-AIneutral
11/09/21 4:10 PMNasdaq : ZLAB earningsZai Lab Announces Third Quarter 2021 Financial Results and Corporate UpdatesCompany to Host Conference Call and Webcast on November 10, 2021, at 8:00 a.m. EST SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBERHEA-AIvery positive
11/09/21 8:00 AMNasdaq : BPMC, ZLAB Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater ChinaBlueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 andRHEA-AIpositive
11/09/21 8:00 AMNasdaq : ZLAB Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater ChinaRHEA-AIpositive